124 related articles for article (PubMed ID: 35072574)
1. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Apr; 29(3):590-600. PubMed ID: 35072574
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M; Gottar-Guillier M; Rossy E
Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Guyader GL; Vieillard V; Paul M
J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
[TBL] [Abstract][Full Text] [Related]
5. In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M; Jeong H; Yun J; Kim J; Kim S; Lee Y; Park SJ
Drugs R D; 2023 Dec; 23(4):363-375. PubMed ID: 37606749
[TBL] [Abstract][Full Text] [Related]
6. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
Hui A; Yin J; Liu W; Zheng K
Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
[TBL] [Abstract][Full Text] [Related]
7. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.
Yun J; Kim J; Chung J; Hwang SJ; Park SJ
Adv Ther; 2019 Jul; 36(7):1700-1714. PubMed ID: 31102205
[TBL] [Abstract][Full Text] [Related]
8. In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Kim SJ; Lee JW; Kang HY; Kim SY; Shin YK; Kim KW; Oh JS; Lim KJ; Kim JY
BioDrugs; 2018 Dec; 32(6):619-625. PubMed ID: 30386977
[TBL] [Abstract][Full Text] [Related]
9. Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Nalenz H; Köpf E; Dietel E
Int J Pharm Compd; 2018; 22(5):417-423. PubMed ID: 30384340
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline) for extended duration.
Vats B; Goyal P; Mathew Z; Ghosh R; Babu MN; Jadav RS; Nair AM; Subbarao M; Bera A; Prakash Sadasivappa K; Kabadi P; Sarkar A; Honnappa CG; Patnaik US; Singh A; Parambath AV; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):299-311. PubMed ID: 33896318
[TBL] [Abstract][Full Text] [Related]
11. Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.
Vieillard V; Le Guyader G; Jallades A; Astier A
J Oncol Pharm Pract; 2024 Jan; 30(1):142-150. PubMed ID: 37078110
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D; Kim J; Yun J; Park SJ
Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
[TBL] [Abstract][Full Text] [Related]
13. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
14. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
Glover ZW; Gennaro L; Yadav S; Demeule B; Wong PY; Sreedhara A
J Pharm Sci; 2013 Mar; 102(3):794-812. PubMed ID: 23225178
[TBL] [Abstract][Full Text] [Related]
15. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas PA; Kuzmission A; Ikeda K; Yasuo S
Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
[TBL] [Abstract][Full Text] [Related]
16. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
Lamanna WC; Heller K; Schneider D; Guerrasio R; Hampl V; Fritsch C; Schiestl M
J Oncol Pharm Pract; 2019 Mar; 25(2):269-278. PubMed ID: 28950806
[TBL] [Abstract][Full Text] [Related]
17. In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima
Kim SJ; Kim KW; Shin YK; Kwon JW; Kang HY; Park YA; Shin JY; Kim SY; Han WY
BioDrugs; 2019 Apr; 33(2):221-228. PubMed ID: 30747341
[TBL] [Abstract][Full Text] [Related]
18. Long-term stability of morphine hydrochloride in 0.9% NaCl infusion polyolefin bags after freeze-thaw treatment and in polypropylene syringes at 5 degrees C + 3 degrees C.
Hecq JD; Godet M; Gillet P; Jamart J; Galanti L
Int J Pharm Compd; 2014; 18(1):78-82. PubMed ID: 24881344
[TBL] [Abstract][Full Text] [Related]
19. Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags.
Trissel LA; Pearson SD
Am J Hosp Pharm; 1994 Feb; 51(3):368-72. PubMed ID: 8160690
[TBL] [Abstract][Full Text] [Related]
20. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5±3°C.
Closset M; Goderniaux N; Colsoul ML; Soumoy L; Bihin B; Jamart J; Odou P; Hecq JD; Galanti L
J Oncol Pharm Pract; 2021 Sep; 27(6):1328-1332. PubMed ID: 32903143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
